Information Provided By: 
Fly News Breaks for June 24, 2015
ESPR
Jun 24, 2015 | 07:25 EDT
UBS said the risk/reward for Esperion is skewed to the upside following the recent pullback in shares, citing several near-term catalysts. The firm sees the possibility of a broader label for its PCSK9 drug than was implied by the vote at the FDA advisory committee meeting, which should drive meaningful upside. UBS reiterated its Buy rating and $140 price target on Esperion shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
